Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.490
+0.1601.92%
Volume:110.99M
Turnover:947.98M
Market Cap:97.82B
PE:23.03
High:8.720
Open:8.460
Low:8.300
Close:8.330
52wk High:11.454
52wk Low:4.463
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.36
T/O Rate:0.96%
Dividend:0.24
Dividend Rate:2.82%
EPS(LYR):0.369
ROE:10.83%
ROA:5.65%
PB:2.60
PE(LYR):23.03
PS:3.29

Loading ...

CSPC Pharmaceutical Group Stock Falls 4.5% in Hong Kong

Dow Jones
·
Feb 26

CSPC Pharma Retains "Outperform" Rating with HK$13.07 Target from Haitong International

Stock News
·
Feb 25

CSPC Pharmaceutical Group Stock Slips 5.2% in Hong Kong

Dow Jones
·
Feb 24

CSPC Pharma's AstraZeneca Deal Suggests Undervalued Drug Pipeline -- Market Talk

Dow Jones
·
Feb 24

Assessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After New Obesity And Pain Drug Trial Clearances

Simply Wall St.
·
Feb 18

CSPC Pharmaceutical (1093) Receives U.S. FDA Nod for Monthly GLP-1/GIP Dual-Biased Injection Trial

Bulletin Express
·
Feb 16

CSPC (1093) Gains Clinical Trial Approval for Ropivacaine Long-acting Injection

Bulletin Express
·
Feb 16

CSPC PHARMA's Long-Acting GLP-1/GIP Dual Agonist Receives FDA Clearance for US Clinical Trials

Stock News
·
Feb 16

BRIEF-CSPC Pharmaceutical Obtains FDA Approval For SYH2082 Clinical Trial

Reuters
·
Feb 16

CSPC PHARMA's Long-Acting Ropivacaine Injection Receives Clearance for Clinical Trials in China

Stock News
·
Feb 16

CSPC Pharmaceutical Group Receives FDA Approval for SYH2082 Clinical Trial in the US

Reuters
·
Feb 16

CSPC Pharmaceutical Group Wins Clinical Trial Approval for Long-Acting Ropivacaine Injection in China

Reuters
·
Feb 16

CSPC Pharmaceutical - Approval From Nmpa

THOMSON REUTERS
·
Feb 16

CSPC Pharmaceutical - Ropivacaine Long-Acting Injection Approved for Clinical Trials in China

THOMSON REUTERS
·
Feb 16

CSPC Pharmaceutical Group Stock Rallies 1.6% in Hong Kong, Outperforms Competitors

Dow Jones
·
Feb 11

AstraZeneca Signs Global Rights Agreement With CSPC for Injectable Weight Management Portfolio

Reuters
·
Feb 10

AstraZeneca Projects Double-Digit EPS Growth Following $18.5 Billion CSPC Pharma Partnership

Deep News
·
Feb 10

CSPC Pharmaceutical Group Stock Rises 5.5% in Hong Kong, Outperforms Competitors

Dow Jones
·
Feb 10

Biopharmaceutical Stocks Show Broad Gains with CSPC PHARMA Leading with Over 7% Rise

Deep News
·
Feb 10

CSPC PHARMA Shares Climb Over 3% as Analysts Foresee Additional Out-Licensing Deals for EGFR ADC and R&D Platform

Stock News
·
Feb 09